Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PTGIR | P43119 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1943271 | 0.90 | CYP3A4 (0.56) | CYP3A4PTGDR2TBXA2RPTGDRBCHE | |
| SCHEMBL1009997 | 0.89 | CYP3A4 (0.64) | CYP3A4PTGDR2TBXA2RPTGDRBCHE | |
| SCHEMBL1009931 | 0.84 | PTGDR2 (0.55) | CYP3A4PTGDR2TBXA2RPTGDRCYP2C9 | |
| SCHEMBL13521854 | 0.83 | CYP3A4 (0.74) | CYP3A4PTGDR2CYP2C9 | |
| Am-461 SCHEMBL349848 | 0.82 | CYP3A4 (1.00) | CYP3A4PTGDR2CYP2C9 | |
| Am-461 SCHEMBL29567409 | 0.82 | CYP3A4 (1.00) | CYP3A4PTGDR2CYP2C9 | |
| SCHEMBL13580761 | 0.81 | PTGDR2 (0.46) | CYP3A4PTGDR2TBXA2RPTGDRCYP2C9 | |
| SCHEMBL1009864 | 0.81 | PTGDR2 (0.46) | CYP3A4PTGDR2TBXA2RPTGDRCYP2C9 | |
| Am-461 SCHEMBL14715969 | 0.81 | CYP3A4 (0.98) | CYP3A4PTGDR2CYP2C9 | |
| SCHEMBL348737 | 0.81 | CYP3A4 (0.72) | CYP3A4PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426449-B2 | Aminoalkylphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-04-23 | — | — | US | claimed |
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | claimed |
| EP-2268611-A2 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009145989-A2 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | WO | claimed |
| US-8426449-B2 | Aminoalkylphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426449-B2 | Aminoalkylphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426449-B2 | Aminoalkylphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2268611-A2 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009145989-A2 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009145989-A2 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130453-A1 | AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | CYP3A4 1269/4885PTGDR2 2/4885TBXA2R 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.